FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension

समान संसाधन

• Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
  द्वारा: Alten, Rieke, और अन्य
  प्रकाशित: (2020)
• Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab
  द्वारा: Schreiber, Stefan, और अन्य
  प्रकाशित: (2020)
• Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
  द्वारा: Genovese, Mark C, और अन्य
  प्रकाशित: (2020)
• Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects
  द्वारा: Puri, Adeep, और अन्य
  प्रकाशित: (2017)
• Real‐life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data
  द्वारा: Kapoor, Sanjiv, और अन्य
  प्रकाशित: (2019)